Rising Tide of Antibiotic Resistance in Sub-Saharan Africa: A Meta-Analysis of Vibrio cholerae Susceptibility(2014-2024)

IF 4.8 2区 医学 Q1 INFECTIOUS DISEASES
Dr Yahaya Mohammed , Dr Ahmed Olowo-okere
{"title":"Rising Tide of Antibiotic Resistance in Sub-Saharan Africa: A Meta-Analysis of Vibrio cholerae Susceptibility(2014-2024)","authors":"Dr Yahaya Mohammed ,&nbsp;Dr Ahmed Olowo-okere","doi":"10.1016/j.ijid.2024.107387","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Antibiotics are commonly used alongside rehydration therapy in the management of cholera. Their efficacy is however increasingly compromised by global rise of antibiotic-resistant bacteria. This is particularly concerning in sub-Saharan Africa, where cholera is endemic, recurrent and access to effective antibiotics is highly limited. This study aims to systematically evaluate data on antibiotic resistance in Vibrio cholerae isolates across sub-Saharan Africa.</div></div><div><h3>Methods</h3><div>We conducted a systematic literature search across PubMed, Scopus, Embase, Google scholar and Web of Science databases to identify articles reporting the susceptibility profiles of Vibrio cholerae isolates from cholera patients between 2014 and April 2024. We utilized the Freeman-Tukey double arcsine transformation to estimate the weighted pooled resistance (WPR). Heterogeneity of the data and bias were analyzed with random effect model meta-analysis and funnel plot. The data were analyzed using Comprehensive Meta-Analysis Software Version 4.0 (Biostat, Englewood, NJ, USA)</div></div><div><h3>Results</h3><div>This meta-analysis presents results of antibiotics resistance profile of 1761 V. cholerae isolates from 12 countries. The isolates were predominantly O1 El tor serogroup with 71.2% ogawa and 28.8% inaba biotypes. Majority of the studies were from Nigeria (6/22) followed by Ghana (4/22) and Kenya (3/22). Ciprofloxacin (19/22), tetracycline (18/22) and trimethoprim-sulfamethoxazole (17/22) were the most frequently studied antibiotics. The results revealed varying rates of resistance among different antibiotics, with co-trimoxazole 77.99% (C.I.: 0.6702-0.8606) exhibiting the highest resistance, followed by nalidixic acid 67.25 % (C.I.: 0.4625-0.8305) and amoxicillin-clavulanate 74.91 % (C.I.: 0.411- 0.927). The WPR of tetracycline, ciprofloxacin and chloramphenicol were respectively 29.74 % (C.I.: 0.1912-0.4313), 8.41% (C.I.: 0.0423-0.1605) and 32.71 % (0.1708-0.5343). Regional analysis revealed that WPR of tetracycline and ciprofloxacin were highest in Nigeria (60.75 %) and Zambia (59.04 %) respectively. The WPR for tetracycline and ciprofloxacin increased notably after 2020 COVID-19 pandemic, rising from 16.6% (0.0687-0.3499) to 39.1% (0.2314-0.5784) and from 1.5% (0.0042-0.0552) to 16.2% (0.0802-0.2990), respectively. This upward trend was also observed across other antibiotics studied.</div></div><div><h3>Discussion</h3><div>The meta-analysis reveals a worrying rise in antibiotic resistance among V. cholerae in sub-Saharan Africa. The increasing antibiotic resistance observed both before and after 2020 could potentially be associated with the global rise in antibiotic resistance, possibly stemming from the overuse of antibiotics during the COVID-19 pandemic.</div></div><div><h3>Conclusion</h3><div>The findings underscore the alarming prevalence of antibiotic resistance among V. cholerae isolates in sub-Saharan Africa. We also noted a lack of data on V. cholerae susceptibility in several countries. With high rates of resistance observed against commonly used antibiotics, the effectiveness of current treatment regimens for cholera is severely compromised. Urgent measures such as enhanced surveillance, judicious antibiotic use, and implementation of antibiotic stewardship are thus urgently needed to address this growing public health threat in the region.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"152 ","pages":"Article 107387"},"PeriodicalIF":4.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224004624","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Antibiotics are commonly used alongside rehydration therapy in the management of cholera. Their efficacy is however increasingly compromised by global rise of antibiotic-resistant bacteria. This is particularly concerning in sub-Saharan Africa, where cholera is endemic, recurrent and access to effective antibiotics is highly limited. This study aims to systematically evaluate data on antibiotic resistance in Vibrio cholerae isolates across sub-Saharan Africa.

Methods

We conducted a systematic literature search across PubMed, Scopus, Embase, Google scholar and Web of Science databases to identify articles reporting the susceptibility profiles of Vibrio cholerae isolates from cholera patients between 2014 and April 2024. We utilized the Freeman-Tukey double arcsine transformation to estimate the weighted pooled resistance (WPR). Heterogeneity of the data and bias were analyzed with random effect model meta-analysis and funnel plot. The data were analyzed using Comprehensive Meta-Analysis Software Version 4.0 (Biostat, Englewood, NJ, USA)

Results

This meta-analysis presents results of antibiotics resistance profile of 1761 V. cholerae isolates from 12 countries. The isolates were predominantly O1 El tor serogroup with 71.2% ogawa and 28.8% inaba biotypes. Majority of the studies were from Nigeria (6/22) followed by Ghana (4/22) and Kenya (3/22). Ciprofloxacin (19/22), tetracycline (18/22) and trimethoprim-sulfamethoxazole (17/22) were the most frequently studied antibiotics. The results revealed varying rates of resistance among different antibiotics, with co-trimoxazole 77.99% (C.I.: 0.6702-0.8606) exhibiting the highest resistance, followed by nalidixic acid 67.25 % (C.I.: 0.4625-0.8305) and amoxicillin-clavulanate 74.91 % (C.I.: 0.411- 0.927). The WPR of tetracycline, ciprofloxacin and chloramphenicol were respectively 29.74 % (C.I.: 0.1912-0.4313), 8.41% (C.I.: 0.0423-0.1605) and 32.71 % (0.1708-0.5343). Regional analysis revealed that WPR of tetracycline and ciprofloxacin were highest in Nigeria (60.75 %) and Zambia (59.04 %) respectively. The WPR for tetracycline and ciprofloxacin increased notably after 2020 COVID-19 pandemic, rising from 16.6% (0.0687-0.3499) to 39.1% (0.2314-0.5784) and from 1.5% (0.0042-0.0552) to 16.2% (0.0802-0.2990), respectively. This upward trend was also observed across other antibiotics studied.

Discussion

The meta-analysis reveals a worrying rise in antibiotic resistance among V. cholerae in sub-Saharan Africa. The increasing antibiotic resistance observed both before and after 2020 could potentially be associated with the global rise in antibiotic resistance, possibly stemming from the overuse of antibiotics during the COVID-19 pandemic.

Conclusion

The findings underscore the alarming prevalence of antibiotic resistance among V. cholerae isolates in sub-Saharan Africa. We also noted a lack of data on V. cholerae susceptibility in several countries. With high rates of resistance observed against commonly used antibiotics, the effectiveness of current treatment regimens for cholera is severely compromised. Urgent measures such as enhanced surveillance, judicious antibiotic use, and implementation of antibiotic stewardship are thus urgently needed to address this growing public health threat in the region.
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
18.90
自引率
2.40%
发文量
1020
审稿时长
30 days
期刊介绍: International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信